Evercore ISI upgraded Repligen (RGEN) to Outperform from In Line with a price target of $155, up from $130. The firm believes the bioprocessing solutions end market is “relatively insulated” from macro headwinds and is now back now back to a normal high-single-digit growth cadence. Evercore believes Repligen’s new business is delivering while its new modalities overhang “is seemingly removed.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen price target raised to $205 from $204 at RBC Capital
- Repligen Appoints Violetta Hughes as Chief Accounting Officer
- Repligen announces strategic partnership with Novasign
- Repligen’s Strong Market Position and Growth Prospects Justify Buy Rating
- Repligen’s Earnings Call Highlights Robust Growth